These results are largely expected since both SGLT2i and GLP-1RA positively influence renal outcome with different mechanisms, whereas GLP-1RA exert minor effects on hHF,, except in non-diabetic patients with obesity [23]
Gut microbiota dysbiosis drives MASLD in large part through the gutliver axis: increased intestinal permeability allows bacterial products (LPS/PAMPs), excess free fatty acids and other microbe-derived metabolites to enter the portal blood, directly engaging hepatic immune cells and metabolic pathways to promote insulin resistance, oxidative stress, inflammation, steatosis and fibrogenesis
DOI: 10.3390/biom13040688
Some studies have indicated that patients prescribed semaglutide, the active ingredient in Ozempic, for diabetes or weight loss may be at increased risk of developing NAION
Insurance coverage varies significantlymany plans do not cover Wegovy for weight management (only diabetes), creating access barriers